Business Wire

MA-EXAGRID

Share
ExaGrid Named to First-Ever MES Matters – Key Vendors Serving the Midmarket List

ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that Midsize Enterprise Services (MES), a brand of The Channel Company , has recognized ExaGrid on its 2022 MES Matters- Key Vendors Serving the Midmarket list.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005185/en/

The MES Matters list recognizes vendors that have proven themselves to be forward-thinking technology providers offering solutions that support the growth and innovation of midmarket organizations.

MES defines the midmarket as an organization with an annual revenue of $50M-$2B and/or 100-2500 total supported users/seats. Companies were selected due to their go-to-market strategy, how they serve the midmarket, and the strength of their midmarket product portfolios.

ExaGrid focuses on the Midmarket to the Large Enterprise and offers the most value to customers who back up 50TB to 100s of PB of data, and keep data for long-term retention. Midmarket organizations in particular have a complex set of requirements for backup storage that include: working across a wide range of operating systems, network topologies and distributed environments, stringent security requirements, and managing massive data growth. In addition, Midmarket organizations have tight IT resources and budget dollars.

ExaGrid Tiered Backup Storage appliances were architected to work with all major backup applications and in any environment but with the easiest installation, easiest management, and the lowest cost up front and over time. Midmarket organizations need a solution that brings the appropriate compute with capacity to handle large data loads and massive data growth, with the least management possible. ExaGrid’s full appliances in a single system bring a scale-out architecture to backup storage at a price that is affordable. In addition, ExaGrid’s tiered storage architecture includes a non-network-facing repository (providing a virtual air gap) where data is stored as immutable objects, and enables a delayed delete policy with its Retention Time-Lock for Ransomware Recovery feature, and this functionality is an important consideration for Midmarket organizations in the wake of increasing ransomware and malware attacks.

“ExaGrid’s Tiered Backup Storage offers the key items that Midmarket organizations need for their backup infrastructure: A scale-out architecture that allows them to add appliances to their system as their data grows, so they only pay for what they need, with no costly forklift upgrades, as well as a backup storage solution that is ready for ransomware recovery,” said Bill Andrews, President and CEO. “We are honored to be recognized among the leading vendors that serve Midmarket organizations and look forward to providing more organizations with a backup storage solution that offers the best performance for the best value, up front and over time.”

“The MES Matters list is designed to recognize key vendors that are invested in the growth and development of midmarket organizations which according to Harvard Business Review 3/21, represent only 3% of US businesses but are responsible for 33% of private sector GDP and employment. Technology is often designed and priced for either the consumer in mind, or the extreme opposite for the heavy enterprise in mind. Midmarket organizations are unique in the way they are structured and as a result their technology needs and requirements from features to pricing are very different than other market segments” said Adam Dennison, VP Midsize Enterprise Services, The Channel Company. “The vendors and executives identified on this first-ever MES Matters list have shown a consistent commitment to help midmarket organizations succeed and thrive, they should be recognized and commended for their dedication to this important market segment”.

The MES Matters list is featured online at https://www.crn.com/rankings-and-lists/mes2022.htm

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories .

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

About The Channel Company

The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers, and end users. Backed by more than 30 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com

Follow The Channel Company : Twitter , LinkedIn , and Facebook .

© 2022 The Channel Company, LLC. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

Link:

ClickThru

Social Media:

https://www.facebook.com/ExaGrid/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye